Preventing the progressive nature of type 2 diabetes.
D002219:Carbamates / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D061268:Insulin Lispro; D008687:Metformin / Q000627:therapeutic use; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077205:Pioglitazone; D010880:Piperidines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones
D002219:Carbamates; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D010880:Piperidines; D013844:Thiazoles; D045162:Thiazolidinediones; D000077715:Nateglinide; D010649:Phenylalanine; C072379:repaglinide; D008687:Metformin; D000077205:Pioglitazone